About Atopic Dermatitis Drugs
Atopic dermatitis is a common, chronic, relapsing, inflammatory disease that primarily affects young children. Atopy refers to an inherited tendency to produce IgE antibodies, whereas, dermatitis means inflammation of the skin. Atopic dermatitis is associated with asthma, inhalant allergies (hay fever), and chronic dermatitis. In this condition, the skin becomes extremely itchy and inflamed, which causes redness, cracking, weeping, swelling, vesicle formation, crushing, and scaling. Atopic dermatitis is very common worldwide, and its prevalence rate is increasing. The data estimates suggest that nearly 60% of the patients develop symptoms in the first year of life, and 88%-92% develop symptoms before the age of five.
Technavio’s analysts forecast the global atopic dermatitis drugs market to grow at a CAGR of 4.20% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global atopic dermatitis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of atopic dermatitis drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Atopic Dermatitis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• LEO Pharma
• Mylan
• Valeant
• Bayer HealthCare
• Encore Dermatology
Market driver
• Growing prevalence of food allergies exacerbating atopic dermatitis
• For a full, detailed list, view our report
Market challenge
• Poor patient adherence due to inadequate information on drug usage
• For a full, detailed list, view our report
Market trend
• Increasing M&A leading to market consolidation
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Key market highlights
PART 05: An overview of atopic dermatitis
PART 06: Pipeline analysis
PART 07: Market landscape
• Market overview
• Market size and forecast
PART 08: Five force analysis
PART 09: Market segment by ROA
• Oral ROA
• Topical ROA
• Injectable ROA
PART 10: Geographical segmentation
• Atopic dermatitis drugs market in Americas
• Atopic dermatitis drug market in EMEA
• Atopic dermatitis drugs market in APAC
PART 11: Market drivers
• Growing prevalence of food allergies exacerbating atopic dermatitis
• Growing focus on systemic therapies
• Increasing use of pharmacological products in developing countries
PART 12: Impact of drivers
PART 13: Market challenges
• Black box warning for Elidel and Protopic
• Highly genericized market
• Poor patient adherence due to inadequate information on drug usage
PART 14: Impact of drivers and challenges
PART 15: Market trends
• Increasing M&A leading to market consolidation
• Launch of first biologic for atopic dermatitis
• Growing focus on novel drugs
PART 16: Vendor landscape
• Competitive scenario
• LEO Pharma
• Mylan
• Valeant
• Bayer HealthCare
• Encore Dermatology
PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Global atopic dermatitis drugs market: Key customer segments
Exhibit 02: Pipeline analysis by phase 2016
Exhibit 03: Key pipeline molecules
Exhibit 04: Global atopic dermatitis drugs market: Snapshot
Exhibit 05: Global atopic dermatitis drugs market 2016-2021 ($ millions)
Exhibit 06: Global atopic dermatitis drugs market: Opportunity analysis
Exhibit 07: Five force analysis
Exhibit 08: Global atopic dermatitis drug market by ROA 2016
Exhibit 09: Oral ROA for atopic dermatitis
Exhibit 10: Global atopic dermatitis drugs market by geography 2016
Exhibit 11: Global atopic dermatitis drugs market by geography 2021
Exhibit 12: Market scenario: Americas
Exhibit 13: Atopic dermatitis drugs market in Americas 2016-2021 ($ millions)
Exhibit 14: Market scenario: EMEA
Exhibit 15: Atopic dermatitis drugs market in EMEA 2016-2021 ($ millions)
Exhibit 16: Market scenario in APAC
Exhibit 17: Atopic dermatitis drugs market in APAC 2016-2021 ($ millions)
Exhibit 18: Systemic therapy for atopic dermatitis.
Exhibit 19: Impact of drivers
Exhibit 20: Impact of drivers and challenges
Exhibit 21: New and emerging treatments for atopic dermatitis: Agents in Phase II clinical trials.
Exhibit 22: Global atopic dermatitis drugs market: Competitive structure analysis 2016
Exhibit 23: Competitive analysis of global atopic dermatitis drugs market
Exhibit 24: Market penetration of vendors in global atopic dermatitis drug market 2016
Exhibit 25: LEO Pharma: Key highlights
Exhibit 26: LEO Pharma: Strength assessment
Exhibit 27: LEO Pharma: Strategy assessment
Exhibit 28: LEO Pharma: Opportunity assessment
Exhibit 29: LEO Pharma: YoY revenue and growth rate of Protopic 2014-2016 ($ million)
Exhibit 30: Mylan: Key highlights
Exhibit 31: Mylan: Strength assessment
Exhibit 32: Mylan: Strategy assessment
Exhibit 33: Mylan: Opportunity assessment
Exhibit 34: Valeant: Key highlights
Exhibit 35: Valeant: Strength assessment
Exhibit 36: Valeant: Strategy assessment
Exhibit 37: Valeant: Opportunity assessment
Exhibit 38: Bayer HealthCare: Key highlights
Exhibit 39: Bayer HealthCare: Strength assessment
Exhibit 40: Bayer HealthCare: Strategy assessment
Exhibit 41: Bayer HealthCare: Opportunity assessment
Exhibit 42: Encore Dermatology: Key highlights
Exhibit 43: Encore Dermatology: Strength assessment
Exhibit 44: Encore Dermatology: Strategy assessment
